Who We Work With

“At EMQN, we recognize that strong partnerships are crucial for enhancing healthcare quality. Our collaboration with Microbix exemplifies this belief. Together, we are elevating global standards in Point-of-Care Testing (POCT). Microbix’s high-quality reference materials are vital to the integrity of our EQA schemes, ensuring precise, real-time diagnostics in clinical environments. This partnership transcends mere supply; it is rooted in shared values, innovation, and a collective mission to improve patient outcomes. By joining forces, we are making POCT more reliable, trusted, and impactful across healthcare systems worldwide.”

Simon Patton, Chief Operation Officer

“API believes it is critical that we determine which widely-used MDx assays can or can’t reliably detect H5N1 Flu. Such knowledge is critical for mounting an effective health system response to this emerging pandemic threat. The API team is proud to be collaborating with Microbix and our clinical lab customers to initiate a PT program that fulfills this urgent need.”

Sue Harmer, President of API

“Cervical cancer is preventable by vaccination and HPV screening, but remains a leading cause of death for women in the Indo-Pacific. EPICC aims to reduce the human toll of cervical cancer across the region. A key element to achieve this is making well-controlled molecular HPV tests readily available. Microbix HPV-directed PROCEEDxFLOQ and REDxFLOQ QAPs provide excellent QMS support for such testing by fully emulating patient specimens while being both highly-stable and non-infectious.”

David Hawkes, Director of Medical Microbiology at ACPCC

“In this partnership, we are increasing our IVD presence for the U.S. and further supporting our lab customers in their mission to better provide quality results for their patients and institutions. As well, we believe our ongoing IVD assay development requires custom control and validation panel expertise that is met by Microbix’s competencies.”

Craig Howell, SVP for Marketing